MRK heads into its next earnings cycle with options traders growing more defensive even as short sellers trim positions — a divergence that defines the week's setup.
The clearest signal this week comes from options. The put/call ratio has climbed to 0.86, about one standard deviation above its 20-day mean of 0.78, and its highest reading in over a week. That's not an alarm, but it marks a notable directional shift: for much of April, the PCR ran below 0.70, reflecting a more relaxed options market. The drift higher — from 0.67 in early April to 0.86 now — tracks closely with the stock's softer month, down 6.4% over 30 days to $113.15. The next earnings call is confirmed for May 26, and the put-heavy skew suggests at least some hedging against that event.
Short interest, by contrast, tells a less agitated story. At roughly 1% of free float, there is no meaningful short-side crowding here. The position peaked near mid-April — when SI briefly touched above 1.5% on some estimates — then eased sharply. Tuesday's session saw an estimated 9% single-day drop in short shares outstanding, pulling the level back to around 25.4 million shares. Borrow remains cheap at 0.42%, essentially unchanged over the month, and the lending pool is generously available. That combination signals no squeeze pressure and no conviction short thesis building in the background.
The Street leans constructive on , though with some target-price discipline emerging. Citigroup reinstated coverage this week at Neutral with a $125 target — sitting only modestly above the current price. Wells Fargo maintained its Overweight rating earlier in the week but trimmed its target from $150 to $145, a sign that confidence in the bull case is intact but near-term risk tolerance has moderated. The consensus mean target is $129.74, implying roughly 15% upside from current levels, and UBS and JPMorgan both raised targets in recent weeks. Bears anchor their concern on Keytruda patent expiration risk — the eventual loss of exclusivity on Merck's blockbuster oncology drug remains the dominant structural worry. Bulls counter with a deep pipeline, strong animal health revenues, and EPS momentum that ranks in the 81st-to-83rd percentile on both 30- and 90-day measures.
Valuation has compressed. The PE multiple has declined nearly two full turns over the past month to 17.1x. EV/EBITDA has also retreated, down roughly 0.7x over 30 days to 12.3x. For a large-cap pharma with a 3% forward yield — scoring in the 99th percentile for dividend quality — that compression represents either a genuine buying opportunity or the market pricing in longer-run headwinds from the Keytruda cliff. The market cap is approximately $279 billion, and the EV/EBITDA compression suggests the market is reassessing that premium relative to peers.
Insider activity carries little signal value this week. The recent trades are small award grants and sub-$600,000 open-market sells by senior vice presidents and the HR director — routine compensation-linked activity, not directional.
The Q1 print in late April produced a 1.1% next-day gain, a muted response that points to an in-line result absorbed without fanfare. The February report saw a 4.4% one-day move and a 3.3% five-day follow-through — a stronger reaction, though still not extreme by pharma standards. Against that backdrop, peers had a divergent week: JNJ was nearly flat while GSK fell 8.4% and AZN dropped 4.1%, making Merck's 2.8% weekly gain look relatively resilient. LLY surged 13.1% on the week, a reminder of how violently single-catalyst moves can re-order pharma relative performance.
The May 26 earnings call is the next inflection point — the setup entering it is mildly defensive in options, quiet in borrow markets, and carrying a Street that has just begun trimming targets at the margin even while holding positive ratings.
See the live data behind this article on ORTEX.
Open MRK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
